Why it remains the mainstay for newly diagnosed metastases and tumors
Podcast content: This podcast is available to listen to online.
Listen to podcast online (https://www.buzzsprout.com/2241774/13511893)
Cleveland Clinic Cancer Advances · Stereotactic Radiosurgery in the Treatment Landscape for Brain Metastases
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Brain metastases are about 10 times more common than primary brain tumors in adults, so it is really important that medical oncologists and primary care doctors are tuned into the possibility of their patients with cancer developing brain metastases,” says neurosurgeon Gene Barnett, MD, MBA, Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center. “The treatment options are better if we get to these metastases when they are smaller and/or asymptomatic.”
One treatment option is stereotactic radiosurgery, a minimally invasive intervention that uses targeted radiation beams to treat brain tumors and other abnormalities. In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Barnett discusses the evolution of traditional surgical approaches for treating patients with brain metastases and the ability of stereotactic radiosurgery to deliver superior outcomes. He provides insight on the following:
Click the podcast player above to listen to the episode now, or read on for a short edited excerpt.
Podcast host Dale Shepard, MD, PhD: What does [stereotactic radiosurgery] look like from a patient perspective, in terms of what their experience is as they undergo the treatment and how well they’re likely to do? When I see patients in clinic and I tell them they have a lung met or a liver met, they’re not nearly as frightened as when I tell them they have a brain met. So how do we reassure patients?
Advertisement
Dr. Barnett: Well, I think that’s totally understandable because people understand the brain is who we are and allows us to do what we want to do. Many people know, or know of, people who have had brain tumors and have not done well. I think the point of reassurance is that we can actually do a really good job of controlling brain metastases these days with radiosurgery, to the extent that most people who have brain metastases don’t die from them — rather, they die of their systemic disease and their brain disease is under control. For the vast majority of brain metastases, the control rate is upwards of 90% to 95%. And with the staged technique, the control is typically durable. So, I think that giving patients the facts should be consoling. You don’t want to sugarcoat things, but the facts are that the outcome is actually probably a lot better than what they were thinking.
Advertisement
Advertisement
Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%
New program will help patients improve fitness and manage weight after cancer treatment
Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia
NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations
Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients
Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects
Reduced radiation for lymph node areas reduces side effects
Large Cleveland Clinic analysis may help resolve a longstanding question over optimal fractionation